Abstract Number: 1747 • 2015 ACR/ARHP Annual Meeting
Predictors of Survival on Anti-TNF in an Observational Cohort of Patients with Ankylosing Spondylitis: The Role of MRI Parameters of Inflammation and Structural Damage
Background/Purpose: There has been no data reported evaluating MRI parameters of inflammation and structural damage. We aimed to identify factors influencing survival on anti-TNF therapy…Abstract Number: 2882 • 2015 ACR/ARHP Annual Meeting
Baseline Extent of Damage at the Spine Predicts Radiographic Progression in Korean Patients Using Golimumab for Ankylosing Spondylitis
Background/Purpose: Ankylosing spondylitis (AS) is a chronic rheumatic disease associated with radiographic damage of the spine. Golimumab had consistent efficacy in controlling disease activity through…Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…Abstract Number: 1686 • 2015 ACR/ARHP Annual Meeting
Body Mass Index Is Associated with Hip Arthritis in Patients with Ankylosing Spondylitis
Background/Purpose: To evaluate the clinical courses and associated factors of hip arthritis in patients with ankylosing spondylitis (AS). Methods: In this retrospective analysis, we evaluated…Abstract Number: 1748 • 2015 ACR/ARHP Annual Meeting
Degenerative Changes at the Lumbar Spine in Patients with Axial Spondyloarthritis and Non-Specific Mechanical Low Back Pain: A Magnetic Resonance Imaging Study
Background/Purpose: Magnetic resonance imaging (MRI) has become an invaluable tool for early diagnosis of axial spondyloarthritis (axSpA) and several MRI-based studies have identified SpA-related inflammatory…Abstract Number: 2887 • 2015 ACR/ARHP Annual Meeting
Safety and Tolerability of Secukinumab in Patients with Active Ankylosing Spondylitis: Pooled Safety Analysis of Two Phase 3, Randomized, Controlled Trials
Background/Purpose: Secukinumab, an anti–interleukin-17A monoclonal antibody, improved the signs and symptoms of ankylosing spondylitis (AS) in 2 Phase 3, randomized, double-blind, placebo (PBO)-controlled studies, MEASURE…Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…Abstract Number: 1691 • 2015 ACR/ARHP Annual Meeting
The Presence of Fibromialgia May Influence the Clinimetric Evaluation of Patients with Ankylosing Spondylitis, but Has No Impact on Disease Activity Assessment
Background/Purpose: Fibromyalgia (FM) can be present concomitantly in patients with Ankylosing Spondylitis (AS). It may overestimate the evaluation of disease activity, resulting in more intensive…Abstract Number: 2062 • 2015 ACR/ARHP Annual Meeting
How Reliable Is Self-Evaluation of Symptoms of Inflammatory Back Pain By Patients?
Background/Purpose: Inflammatory back pain (IBP) is regarded as an important clinical parameter of axial spondyloarthritis (axSpA) and is often used in a diagnostic approach. Usually…Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting
Statin Treatment in Patients with Ankylosing Spondylitis
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…Abstract Number: 2829 • 2014 ACR/ARHP Annual Meeting
Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality
Background/Purpose OnSpA is a population-based study of spondyloarthritis (SpA) based on a provincial population of over 13 million. Patients with SpA are thought to be…Abstract Number: 2571 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index
Background/Purpose Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD), but the mediators of this increased risk are not known. Obesity is…Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…Abstract Number: 595 • 2014 ACR/ARHP Annual Meeting
Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort
Background/Purpose: The current concept of axial Spondyloarhtritis (axSpA) considers non-radiographic axSpA (nr-axSpA) and Ankylosing Spondylitis (AS) as two stages of one disease. There are limited…Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 57
- Next Page »